首页> 外文期刊>World Journal of Cardiovascular Surgery >End Organ Recovery and Survival with the QuadroxD Oxygenator in Adults on Extracorporeal Membran Oxygenation
【24h】

End Organ Recovery and Survival with the QuadroxD Oxygenator in Adults on Extracorporeal Membran Oxygenation

机译:在体外膜氧合下使用QuadroxD氧合器在成人中的最终器官恢复和生存

获取原文
           

摘要

Introduction: Extracorporeal Membrane Oxygenation (ECMO) is used in selected patient with cardiogenic and/or re- spiratory shock. We report our experience with standardized management protocols and the application of the Qua- droxD oxygenator with a centrifugal pump to maximize end-organ recovery and improve survival. Methods: This is an Internal Review Board (IRB) approved, single institution retrospective study of end-organ recovery and survival in pa- tients who required ECMO for cardiogenic and/or respiratory shock between July 2010 and June 2011. Results: Sixteen patients (median age: 46 years) were initiated on either Veno-Arterial (VA) or Veno-Venous (VV) ECMO. Cardiogenic shock, acute respiratory distress syndrome (ARDS) and a combined respiratory and cardiogenic compromise were the primary indications for ECMO in 8 (50%), 5 (31%) and 3 (19%) patients respectively. The median time on ECMO was 8 days (range: 4 - 26 days). Twelve patients (75%) were successfully weaned off ECMO, of which four (25%) were bridged to a ventricular assist device (VAD) and eight (50%) were weaned to recovery. All eight patients (100%) that were weaned to recovery and two patients (50%) that were bridged to a VAD were successfully discharged from the hospital, resulting in a discharge rate of 63%. There was an improvement in pre- vs. post-ECMO AST (449 IU/L vs. 63 IU/L, p Conclusion: ECMO using the QuadroxD oxygenator and a centrifugal pump, coupled with standardized management protocols is beneficial in carefully selected patients. Improvement or main- tenance of end-organ function is associated with successful bridge to device therapy and/or increased survival.
机译:简介:体外膜氧合(ECMO)用于某些心源性和/或呼吸休克的患者。我们报告了我们在标准化管理协议以及QuadroxD氧合器与离心泵的应用中的经验,以最大限度地提高最终器官的恢复率并改善生存率。方法:这是一项内部审查委员会(IRB)批准的单机构回顾性研究,研究对象为2010年7月至2011年6月之间需要ECMO进行心源性和/或呼吸休克的患者的终末器官恢复和存活。结果:16例患者(中位数年龄:46岁)是通过静脉-动脉(VA)或静脉-静脉(VV)ECMO启动的。心源性休克,急性呼吸窘迫综合征(ARDS)以及呼吸和心源性综合危害是分别在8(50%),5(31%)和3(19%)患者中进行ECMO的主要指征。 ECMO的平均时间为8天(范围:4-26天)。 12名患者(75%)成功从ECMO断奶,其中4名(25%)桥接至心室辅助装置(VAD),8名(50%)断奶以恢复。断奶至恢复的所有八名患者(100%)和桥接至VAD的两名患者(50%)已成功出院,出院率为63%。 ECMO术前和术后AST分别有所改善(449 IU / L和63 IU / L,p,结论):使用QuadroxD充氧器和离心泵的ECMO,以及标准化的治疗方案,对精心挑选的患者有益。改善或维持终末器官功能与成功过渡至器械治疗和/或增加生存率有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号